Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 5/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148224 | 0.92 | PAOX (0.54) | PAOXCES2ALDH1A1ACHEGAA | |
| SCHEMBL14445051 | 0.92 | PAOX (0.48) | PAOXCES2ALDH1A1ACHEGAA | |
| SCHEMBL15042803 | 0.90 | CES2 (0.50) | PAOXCES2ALDH1A1ACHEGAA | |
| SCHEMBL19532357 | 0.87 | ALDH1A1 (0.45) | PAOXCES2ALDH1A1ACHEGAA | |
| SCHEMBL19532353 | 0.87 | ALDH1A1 (0.45) | PAOXCES2ALDH1A1ACHEGAA | |
| SCHEMBL1921248 | 0.87 | ALDH1A1 (0.50) | PAOXCES2ALDH1A1ACHEGAA | |
| SCHEMBL126775 | 0.87 | ALDH1A1 (0.56) | PAOXCES2ALDH1A1ACHEGAA | |
| SCHEMBL25290890 | 0.86 | GAA (0.50) | PAOXCES2ALDH1A1ACHEGAA | |
| SCHEMBL20932201 | 0.86 | CES2 (0.57) | PAOXCES2ALDH1A1MEN1THRB | |
| SCHEMBL28601607 | 0.86 | CES2 (0.63) | CES2ALDH1A1MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065161-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | DDOST, SDCBP, STT3B | PAOX 1103/4885CES2 149/4885ALDH1A1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.